A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity

被引:153
作者
Masimirembwa, C
Persson, I
Bertilsson, L
Hasler, J
IngelmanSundberg, M
机构
[1] KAROLINSKA INST,INST ENVIRONM MED,DIV MOL TOXICOL,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN
[2] HUDDINGE UNIV HOSP,DEPT MED LAB SCI & TECHNOL,S-14186 HUDDINGE,SWEDEN
[3] UNIV ZIMBABWE,DEPT BIOCHEM,HARARE,ZIMBABWE
关键词
African population; Bantu Zimbabwe; drug metabolism; debrisoquine; genetic polymorphism; interethnic differences;
D O I
10.1046/j.1365-2125.1996.00489.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The debrisoquine hydroxylase (CYP2D6) is polymorphically distributed. Not only are there differences in the proportions of extensive metabolisers to poor metabolisers in various ethnic groups, but there are also pronounced variations in the metabolic capacity among those classified as extensive metabolisers. 2 The mean debrisoquine metabolic ratio of Caucasian extensive metabolisers is lower than that for a number of African populations. In the present study, we have searched for novel CYP2D6 mutations to explain the diminished enzyme activity in African populations. 3 Three Zimbabwean Shona subjects with EM phenotypes (metabolic ratios for debrisoquine of 0.4, 1.5 and 10.5 respectively) were selected and the open reading frame of the CYP2D6 gene of each was sequenced. 4 The subject with metabolic ratio of 10.5 was found to be homozygous for an allele with a nucleotide exchange in exon 2, C-1111-->T causing a (107)Thr-->Ile amino acid exchange in a conserved region of the enzyme. In addition, he was homozygous for the C-2938-->T and (4268)G-->C mutations causing (296)Arg-->Ser and (486)Ser-->Thr amino acid substitution found in the CYP2D6*2 allele. 5 Seventy-six Zimbabwean Shona subjects were subsequently genotyped for the C-1111-->T mutation and for the intron 1 gene conversion present in the CYP2D6*2 gene. The C-1111-->T mutation was found at an allele frequency of 34% and was only present in alleles carrying the gene conversion in intron 1 indicative for the CYP2D6*2 gene. 6 This allele (CYP2D6*17), containing the C-1111-->T, C-2938-->T and (4268)G-->C mutations, was found to be strongly associated with lower capacity for debrisoquine hydroxylation. We therefore postulate that the CYP2D6*17 allele might contribute to the molecular basis of the previously established diminished debrisoquine hydroxylase activity in African Bantu populations.
引用
收藏
页码:713 / 719
页数:7
相关论文
共 30 条
  • [11] THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS
    EICHELBAUM, M
    GROSS, AS
    [J]. PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) : 377 - 394
  • [12] GOTOH O, 1992, J BIOL CHEM, V267, P83
  • [13] HASLER JA, 1994, MOL PHARMACOL, V46, P338
  • [14] GENOTYPING OF POOR METABOLIZERS OF DEBRISOQUINE BY ALLELE-SPECIFIC PCR AMPLIFICATION
    HEIM, M
    MEYER, UA
    [J]. LANCET, 1990, 336 (8714) : 529 - 532
  • [15] JOHANSSON I, 1991, EUR J CLIN PHARMACOL, V40, P553
  • [16] INHERITED AMPLIFICATION OF AN ACTIVE GENE IN THE CYTOCHROME-P450 CYP2D LOCUS AS A CAUSE OF ULTRARAPID METABOLISM OF DEBRISOQUINE
    JOHANSSON, I
    LUNDQVIST, E
    BERTILSSON, L
    DAHL, ML
    SJOQVIST, F
    INGELMANSUNDBERG, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) : 11825 - 11829
  • [17] JOHANSSON I, 1994, MOL PHARMACOL, V46, P452
  • [18] KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209
  • [19] KIMURA S, 1989, AM J HUM GENET, V45, P889
  • [20] A PRELIMINARY 3D MODEL FOR CYTOCHROME-P450 2D6 CONSTRUCTED BY HOMOLOGY MODEL-BUILDING
    KOYMANS, LMH
    VERMEULEN, NPE
    BAARSLAG, A
    DENKELDER, GMDO
    [J]. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1993, 7 (03) : 281 - 289